California State Teachers Retirement System Has $1.40 Million Stock Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

California State Teachers Retirement System lessened its position in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 2.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 61,801 shares of the life sciences company’s stock after selling 1,585 shares during the period. California State Teachers Retirement System owned about 0.08% of Integra LifeSciences worth $1,402,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in IART. Quadrant Capital Group LLC boosted its position in Integra LifeSciences by 5,960.9% in the fourth quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company’s stock valued at $32,000 after buying an additional 1,371 shares in the last quarter. Sterling Capital Management LLC boosted its holdings in shares of Integra LifeSciences by 821.7% in the 4th quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company’s stock worth $49,000 after acquiring an additional 1,931 shares in the last quarter. Covestor Ltd boosted its holdings in shares of Integra LifeSciences by 61.8% in the 4th quarter. Covestor Ltd now owns 5,423 shares of the life sciences company’s stock worth $123,000 after acquiring an additional 2,071 shares in the last quarter. Empowered Funds LLC acquired a new position in shares of Integra LifeSciences in the 4th quarter worth approximately $180,000. Finally, NorthRock Partners LLC acquired a new position in Integra LifeSciences in the fourth quarter worth $251,000. Institutional investors and hedge funds own 84.78% of the company’s stock.

Wall Street Analysts Forecast Growth

IART has been the topic of a number of recent analyst reports. Argus raised Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Monday, March 31st. JPMorgan Chase & Co. reduced their price target on shares of Integra LifeSciences from $24.00 to $12.00 and set an “underweight” rating on the stock in a research report on Tuesday, May 6th. JMP Securities reduced their target price on shares of Integra LifeSciences from $35.00 to $25.00 and set a “market outperform” rating on the stock in a research report on Friday, May 9th. Wells Fargo & Company reduced their target price on shares of Integra LifeSciences from $25.00 to $13.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 6th. Finally, Truist Financial reduced their target price on shares of Integra LifeSciences from $26.00 to $19.00 and set a “hold” rating on the stock in a research report on Friday, April 11th. Four analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $18.63.

Integra LifeSciences Stock Performance

Integra LifeSciences stock opened at $13.56 on Monday. The company’s 50-day moving average is $15.17 and its two-hundred day moving average is $20.56. Integra LifeSciences Holdings Co. has a 1 year low of $11.60 and a 1 year high of $32.66. The company has a market cap of $1.05 billion, a PE ratio of -150.65, a PEG ratio of 0.73 and a beta of 1.16. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Monday, May 5th. The life sciences company reported $0.41 earnings per share for the quarter, missing the consensus estimate of $0.43 by ($0.02). The business had revenue of $382.65 million during the quarter, compared to analyst estimates of $381.17 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company’s quarterly revenue was up 3.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.55 earnings per share. Equities analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.